Balchem Q2 2024 net sales rise 1.2% to $234.1 million; net earnings up 6.5%
Balchem reported second quarter 2024 results for the period ended June 30, 2024, with net sales of $234.1 million, up 1.2%, and GAAP net earnings of $32.1 million, up 6.5%. Adjusted EBITDA was a record $62.3 million, up 5.0%, but the Animal Nutrition and Health segment's sales and earnings from operations fell sharply, which partly offset growth in the other two segments.
Key points
- GAAP diluted earnings per share were $0.98, compared with $0.93 a year earlier; adjusted earnings per share were $1.09, compared with $1.06.
- Human Nutrition and Health sales rose 9.0% to $147.9 million, and Specialty Products sales rose 7.2% to $35.1 million.
- Animal Nutrition and Health sales fell 19.2% to $49.6 million, and its earnings from operations fell 64.9% to $2.7 million.
- Free cash flow was $38.4 million, and the company repaid $35.0 million on its revolving debt, bringing net debt to $202.8 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 26, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.